



**HAL**  
open science

## Profiling of FSHR negative allosteric modulators on LH/CGR reveals biased antagonism with implications in steroidogenesis

Mohammed Akli Ayoub, Romain Yvinec, Gwenhael Jegot, James A. Dias, Sonia-Maria Poli, Anne Poupon, Pascale Crépieux, Eric Reiter

### ► To cite this version:

Mohammed Akli Ayoub, Romain Yvinec, Gwenhael Jegot, James A. Dias, Sonia-Maria Poli, et al.. Profiling of FSHR negative allosteric modulators on LH/CGR reveals biased antagonism with implications in steroidogenesis. *Molecular and Cellular Endocrinology*, 2016, 436, pp.10-22. 10.1016/j.mce.2016.07.013 . hal-01409332

**HAL Id: hal-01409332**

**<https://hal.science/hal-01409332>**

Submitted on 14 Jan 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Profiling of FSHR Negative Allosteric Modulators on LH/CGR Reveals Biased Antagonism with Implications in Steroidogenesis**

Mohammed Akli Ayoub<sup>1,2,\*</sup>, Romain Yvinec<sup>1</sup>, Gwenhaël Jégot<sup>1</sup>, James A. Dias<sup>3</sup>, Sonia-Maria Poli<sup>4</sup>, Anne Poupon<sup>1</sup>, Pascale Crépieux<sup>1</sup>, and Eric Reiter<sup>1</sup>

<sup>1</sup> Biologie et Bioinformatique des Systèmes de Signalisation, INRA, UMR85, Unité Physiologie de la Reproduction et des Comportements, Nouzilly, France; CNRS, UMR7247, Nouzilly, France; Université François-Rabelais, Tours, France; Institut Français du Cheval et de l'Équitation, Nouzilly, France. <sup>2</sup> LE STUDIUM® Loire Valley Institute for Advanced Studies, Orléans, France. <sup>3</sup> Department of Biomedical Sciences, State University of New York at Albany, Albany, New York. <sup>4</sup> Addex Pharma S.A, Plan-les-Ouates, Geneva, Switzerland.

\* **Correspondence:** Institut National de la Recherche Agronomique (INRA) UMR85, CNRS-Université François-Rabelais UMR7247, Physiologie de la Reproduction et des Comportements - Nouzilly 37380, France - Email: [Mohammed.Ayoub@tours.inra.fr](mailto:Mohammed.Ayoub@tours.inra.fr)

## **Abstract**

Biased signaling has recently emerged as an interesting mean to modulate the function of many G protein-coupled receptors (GPCRs). Previous studies reported two negative allosteric modulators (NAMs) of follicle-stimulating hormone receptor (FSHR), ADX68692 and ADX68693, with differential effects on FSHR-mediated steroidogenesis and ovulation. In this study, we attempted to pharmacologically profile these NAMs on the closely related luteinizing/chorionic gonadotropin hormone receptor (LH/CGR) with regards to its canonical Gs/cAMP pathway as well as  $\beta$ -arrestin recruitment in HEK293 cells. The NAMs' effects on progesterone and testosterone production were also assessed in murine Leydig tumor cell line (mLTC-1). We found that both NAMs strongly antagonized LH/CGR signaling in both HEK293 and mLTC-1 cells. ADX68693 appeared more potent than ADX68692 to inhibit hCG-induced cAMP and  $\beta$ -arrestin 2 in HEK293 and mLTC-1 cells whereas no significant difference in their efficacy on hCG-promoted  $\beta$ -arrestin 2 recruitment. Interestingly, differential antagonism of the two NAMs on hCG-promoted steroidogenesis in mLTC-1 cells was observed with significant inhibition of testosterone but not progesterone production. In addition, while ADX68693 totally abolished testosterone, ADX68692 had only a partial effect. These observations suggest biased effects of the two NAMs on LH/CGR-dependent pathways controlling steroidogenesis, which appeared to be different to that previously shown on FSHR. This also illustrates the complexity of signaling pathways controlling FSHR- and LH/CGR-mediated steroidogenesis, suggesting differential implication of cAMP and  $\beta$ -arrestins. Together, our data demonstrate that ADX68692 and ADX68693 are NAMs at the LH/CGR in addition to FSHR. These pharmacological characteristics are important to consider for potential contraceptive and therapeutic applications based on such compounds.

**Keywords:** FSHR, LH/CGR, gonadotropins, steroidogenesis, GPCRs,  $\beta$ -arrestins, bias

## 1. Introduction

The follicle-stimulating hormone receptor (FSHR) and luteinizing/chorionic gonadotropin hormone receptor (LH/CGR) are G protein-coupled receptor (GPCR) members known for their central role in the control of reproduction. Thus, a particular interest has been given to these two receptors with regards to infertility, contraception, estrogen-dependent diseases and other disorders of the reproductive system in medicine {Abma, 1997 #5011}{Behre, 1995 #5019}{Kliesch, 1995 #5037}{Kumar, 1997 #5039} and in animal husbandry. One of the most important aspects in the recent advances on FSHR and LH/CGR is related to the development of small molecules to positively or negatively modulate their activity with the aim to better understand their mechanism of activation and to develop potential therapeutics. These agents may act as orthosteric ligands at the binding site or as allosteric modulators. Indeed, many studies reported small molecules as potential tools and approaches to study underlying mechanisms that enable successful reproduction {Nataraja, 2015 #5044}{Palmer, 2005 #5049}{Arey, 2008 #5013}{Arey, 2002 #5015}{Arey, 2008 #5017}{Guo, 2005 #5074}. Also, small molecules acting on FSHR and LH/CGR have been proposed as alternative oral therapeutics for infertility treatment (agonists) or contraception strategies (antagonists) {Nataraja, 2015 #5044}{Guo, 2005 #5074}. Small molecule agonists of LH/CGR were reported to efficiently induce ovulation {Jorand-Lebrun, 2007 #5033}{van de Lagemaat, 2009 #5062}{van Koppen, 2008 #5066}. Moreover, dimeric molecules were developed with dual effects as antagonist on FSHR {Bonger, 2009 #4060}{Bonger, 2011 #5023} and agonist on LH/CGR {Bonger, 2011 #5023}. For FSHR, recent studies reported interesting small molecules acting either as antagonists {Bonger, 2009 #4060}{Bonger, 2011 #5023}, negative allosteric modulators (NAMs) {Dias, 2011 #3590}{Dias, 2014 #5026} or as positive allosteric modulators (PAMs) or agonists {Sriraman, 2014 #5058}{Yu, 2014 #5071}. Indeed, a thiazolidinone derivative has been reported to activate FSHR signaling in CHO cells and estradiol production in cultured rat granulosa cells {Sriraman, 2014 #5058}. Optimization of substituted benzamides led to more FSHR-selective molecules relative to other closely related GPCRs, such as LH/CGR and thyroid stimulating hormone receptor (TSHR) with better pharmacokinetic properties {Yu, 2014 #5071}.

The initial FSHR NAM molecule reported was ADX61623, which blocked FSHR-mediated cAMP as well as progesterone but not estradiol production in primary rat granulosa cells {Dias, 2011 #3590}. However, ADX61623 did not affect FSH-induced preovulatory follicle development, limiting its application as a nonsteroidal contraceptive {Dias, 2011 #3590}. Two other NAMs, ADX68692 and ADX68693, with structural similarities to ADX61623, were tested and exhibited different antagonistic profile on FSHR in primary rat granulosa cells {Dias, 2014 #5026}. Indeed, while ADX68692 blocked FSHR-promoted cAMP, progesterone and estradiol production, ADX68693 inhibited cAMP and progesterone with the same efficacy as ADX68692 but did not block estradiol production {Dias, 2014 #5026}. This study proposed a potential application of ADX68692 as a nonsteroidal contraceptive since it was also orally active in blocking FSH-induced follicular growth. Based on the functional difference between both analogs, it appeared that the contraceptive effect required that the production of both hormones must be effectively blocked. Both FSHR and LH/CGR are involved in the control of steroid sex hormones, are co-expressed in granulosa cells at specific stages {Ascoli, 2002 #3127}{Simoni, 1997 #3114}{Amsterdam, 1997 #5220}, belong to leucine-rich repeat sub-family of GPCRs and are known to couple to the canonical Gs/cAMP/PKA signaling pathway {Gloaguen, 2011 #3143}{Ulloa-Aguirre, 2011 #3150}. Because of the important structural similarity between FSHR and LH/CGR at the level of their transmembrane domains, one can hypothesize that ADX68692 and ADX68693 may also modulate LH/CGR thereby expanding the spectra of their pharmacological actions.

Moreover, those studies revealed biased inhibitory profiles of ADX68692 *versus* ADX68693 on FSHR-mediated steroidogenesis, albeit the molecular mechanisms underneath remained unknown. Noteworthy, FSHR and LH/CGR have been reported to be susceptible to biased activation {Arey, 2011 #3573}{Landomiel, 2014 #3838}{Wehbi, 2010 #3156}{Tranchant, 2011 #3581}{Ulloa-Aguirre, 2011 #3150} with implication of the non-canonical  $\beta$ -arrestin-dependent signaling pathway {Reiter, 2012 #3046}. In this context, it is still unclear whether the two FSHR NAMs may have biased antagonistic effects involving preferential actions on G proteins *versus*  $\beta$ -arrestins.

In this study, we pharmacologically profiled the two compounds, ADX68692 and ADX68693, on LH/CGR. For this, we investigated their effects on the canonical Gs/cAMP pathway as well as  $\beta$ -arrestin 2 recruitment in HEK293 cells using BRET technology as previously described {Ayoub, 2015 #4823}. Moreover, the cross-reactivity of the two NAMs on LHR was also examined in mLTC-1 cells known to endogenously express LHR {Legardinier, 2005 #5009}, by assessing their effects on hCG-promoted cAMP as well as progesterone and testosterone production.

## **2. Materials and Methods**

### **2.1. Materials and plasmids**

The FSHR NAMs ADX68692 (MW 401.44) and ADX68693 (MW 352.42) were prepared by Addex Pharmaceuticals S.A (Geneva, Switzerland). The specificity of each of the FSHR NAMs was reported previously {Dias, 2014 #5026}. The plasmid encoding human FSHR was generated as previously described {Tranchant, 2011 #3581} and hLHR plasmid was obtained from A. Ulloa-Aguirre (Universidad Nacional Autónoma de México, México, Mexico). The other plasmids encoding the different BRET/FRET sensors and fusion proteins were generously provided as follows: Rluc8-fused hLH/CGR from A. Hanyaloglu (Imperial College, London, UK), yPET- $\beta$ -arrestin 2 from M.G. Scott (Cochin Institute, Paris, France), CAMYEL from L.I. Jiang (University of Texas, Texas, USA), V2R-Rluc8 from K.D. Pflieger (Harry Perkins Institute of Medical Research, Perth, Australia). Recombinant hFSH was kindly gifted by Merck-Serono (Darmstadt, Germany), hCG was kindly donated by Y. Combarrous (CNRS, Nouzilly, France), and desmopressin (DDAVP) a synthetic form of vasopressin was purchased from Sigma-Aldrich (St. Louis, MO, USA). 96- and 384-well white microplates were from Greiner Bio-One (Courtaboeuf, France). Coelenterazine h substrate was purchased from Interchim (Montluçon, France).

### **2.2. Cell culture and transfection**

HEK293 cells were grown in complete medium (DMEM supplemented with 10% (v/v) fetal bovine serum, 4.5 g/l glucose, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1 mM glutamine)(all from Invitrogen, Carlsbad, CA). Transient transfections were performed in 96-well plates using Metafectene PRO (Biontex, München, Germany) following the manufacturer's protocol. Briefly, for each well the different combinations of coding plasmids were used as follows: 200 ng of total plasmid per well were resuspended in 25  $\mu$ l of serum-free DMEM and mixed with Metafectene PRO (0.5  $\mu$ l/well) previously preincubated 5 minutes at room temperature in 25  $\mu$ l serum-free DMEM (2x25  $\mu$ l/well). Then the two solutions of serum-free DMEM containing plasmids and Metafectene PRO were mixed and incubated 20 minutes at room temperature. Cells ( $10^5$  in 200  $\mu$ l/well) were then incubated with the final plasmid-Metafectene PRO mix (50  $\mu$ l/well) and cultured in DMEM supplemented with 10% fetal bovine serum for forty-eight hours before experiments.

### **2.3. BRET measurements**

Forty-eight hours after transfection cells were washed with PBS and BRET measurements were performed depending on the experiments as described previously {Ayoub, 2015 #4823}{Ayoub, 2010 #2576}. For the endpoint dose-response analyses, cells were first preincubated 20 minutes at 37°C in the presence or absence of increasing concentrations of ADX68692 and ADX68693 in 30 µl/well of PBS 1X, HEPES 5 mM. Then, 10 µl/well of increasing doses of hCG prepared 4X in PBS 1X, HEPES 5 mM were added and cells were incubated 30 minutes at 37°C as indicated. Then BRET measurements were performed upon addition of 10 µl/well of coelenterazine h 5X (5 µM final) in PBS 1X, HEPES 5 mM using a Mithras LB 943 plate reader. For the real-time BRET kinetics, cells were first resuspended in 30 µl/well of PBS 1X, HEPES 10 mM containing or not 10 µM of ADX68692 and ADX68693 and then BRET measurements were immediately performed upon addition of 10 µl/well of coelenterazine h (5 µM final) and 10 µl/well of hCG (5-fold concentrated).

### **2.4. cAMP accumulation measured by GloSensor™ assay**

For the measurement of cAMP accumulation, we also used the GloSensor™ cAMP assay (Promega). Growing cells in 96-well plates (80,000 cells per well) in growing medium were incubated overnight at 37°C. On the following day, culture medium was removed and replaced by 100 µl of equilibration medium per well (DMEM-serum free medium with 4% v/v of GloSensor™ cAMP reagent stock solution) and cells were incubated for 2 hours at room temperature. Then, cells were incubated 20 minutes in the presence or absence of increasing concentrations of FSHR NAMs before stimulation with FSH (1.3 nM) and rapid measurement of luciferase signal commenced using a POLARstar OPTIMA luminometer (BMG Labtech, Ortenberg, Germany).

### **2.5. cAMP accumulation measured by HTRF®**

Intracellular cAMP levels were measured using a homogeneous time-resolved fluorescence (HTRF®) cAMP dynamic assay kit (CisBio Bioassays, Bagnol sur Cèze, France). Cells were detached and first resuspended in PBS 1X, 10 mM HEPES, 0.1% BSA containing or 10 µM of ADX68692 and ADX68693. After incubation 20 minutes at 37°C, 5 µl/well (~5000 cells) of cells were seeded into white 384-well microplate and supplemented with 5 µl/well of the stimulation buffer in the absence or presence of hCG as indicated. Cells were then incubated

for 30 minutes at 37°C before lysis by addition of 10 µl/well of the supplied conjugate lysis buffer containing d2-labeled cAMP and Europium cryptate-labeled anti-cAMP antibody, both reconstituted according to the manufacturer's instructions. The plate was incubated for 1 h in the dark at room temperature and fluorescence was measured at 620 nm and 665 nm respectively, 50 ms after excitation at 320 nm using a Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany).

## **2.6. cAMP reporter gene assay**

HEK293 cells were transiently co-transfected with plasmids coding for FSHR or LH/CGR and pSOM-Luc coding for a cAMP-sensitive reporter gene as previously reported {Troispoux, 1999 #5079}. After overnight starvation in DMEM-serum free, cells were first pretreated or not 1 hour at 37°C with 10 µM of ADX68692 and ADX68693 in DMEM-serum free. Then, cells were stimulated 6 hours at 37°C with increasing concentrations of gonadotropins in a final volume of 50 µl/well DMEM-serum free. Luciferase luminescence was measured on Mithras LB 943 plate reader upon addition of 50 µl/well of Bright-Glo™ luciferase substrate in the supplied lysis buffer and incubation of cells 2-5 minutes at room temperature.

## **2.7. Progesterone and testosterone production**

The production of progesterone and testosterone in mLTC-1 cells was assessed using a homogenous time-resolved fluorescence (HTRF®)-based assay (CisBio Bioassays, Codolet, France). Cells were first cultured in 96 well microplates and starved overnight in serum-free RPMI-1640 medium containing 25 mM HEPES and 0.3 g/L of L-glutamine. After pre-treatment 1 hour at 37°C with 10 µM of ADX68692 and ADX68693 prepared in 50 µL/well in serum-free RPMI-1640 medium containing 25 mM HEPES and 0.3 g/L of L-glutamine, cells were stimulated with increasing concentrations of hCG by adding 10 µL/well of hCG prepared 6X in serum-free RPMI-1640 medium containing 25 mM HEPES and 0.3 g/L of L-glutamine. After incubation 24 hours at 37°C, 10 µL of the culture supernatant were transferred to white 384-well microplate and mixed with 10 µL/well of either progesterone or testosterone. HTRF® reagents (5 µL of Europium cryptate-conjugated progesterone or testosterone antibody + 5 µL of d2-conjugated progesterone/testosterone) previously resuspended in the supplied conjugate lysis buffer. The 384-well microplate was then incubated for 1 hour at room temperature in the dark before fluorescence was measured at 620 nm and 665 nm

respectively, 50 ms after excitation at 320 nm using a Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany).

## 2.8. Data and statistical analysis

Data are presented as “% of response” by taking as 100% the maximal responses of the hormone at 100 nM measured in cells non-treated with NAMs in the different assays. The kinetic curves and the sigmoidal dose-responses curves were fitted using Prism 5 graphing software (GraphPad, La Jolla, CA, USA). Two-way ANOVA analysis using Turkey’s multiple comparisons test was used to determine statistically significant differences between the different conditions. \*\*\*  $P < 0.001$ , \*\*  $P < 0.01$ , \*  $P < 0.05$ .

Transduction coefficients ( $R = \tau / K_a$ ) and Bias Factor (B.F.) were obtained after statistical fitting of the operational model (Black & Leff, 1983) for each dose-response curve. Specifically, we followed a similar procedure as in (van der Westhuizen et al., 2013, Namkung et al. 2015 and references therein).

For a given response, for both CG and LH hormones, the two dose-response curves were fitted using the operational model given by eq. 1

$$E = \text{Basal} + (\text{Em} - \text{Basal}) * (\tau [A])^n / ((\tau [A])^n + (K_a + [A])^n), \quad (1)$$

where [A] denotes the concentration of the ligand, to be either hCG or hLH, and E is the quantification of its effect (AMPc BRET changes,  $\beta$ -arr2 recruitment etc...). The Basal parameter is the baseline of the response, Em is the maximal possible response of the system,  $\tau$  is the efficacy,  $K_a$  is the functional equilibrium dissociation constant of the agonist and n is the Hill slope of the transducer function that links occupancy to response. As detailed in (Van der Westhuizen et al., 2013), such equation (1) is badly parametrized to yields proper identification of the transduction coefficient, so we transformed Equation (1), using standard algebraic manipulations, into

$$E = \text{Basal} + (\text{Em} - \text{Basal}) / (1 + ((1 + [A]/10^{\log(K_a)}) / (10^{\log(R)} * [A]))^n), \quad (2)$$

Also, for a given response, Basal, Em and n were imposed to have the same value for all input (response specific parameters) and  $\tau$  and  $K_a$  were hormone specific. For the dms0 input (no NAM), the  $\log(K_a)$  was fixed to 0. and  $\log(R_{\text{dms0}})$ ,  $\log(R_{\text{adx92}})$ ,  $\log(K_a_{\text{adx92}})$ ,  $\log(K_a_{\text{adx93}})$  were found by statistical fitting, together with Basal, Em and n. Data-fitting of such model were performed using the D2D-software, on Matlab 14, and parameter uncertainty was quantified using the profile likelihood method [Raue et al. 2013]. For all dose-response curves, except to the Testosterone response with ADX93 treatment, the transduction coefficient  $\log(R) = \log(\tau / K_a)$  was found to be practically identifiable, with finite narrow confidence interval (of total length from half a log to one log). Mean transduction coefficient together with the standard error on the mean was then estimated. Still for a single dose-response curve, the relative effectiveness between two treatments t1 and t2 (for instance, dms0 vs adx92) is given by

$$\Delta\log(\tau/Ka) = \log(\tau/Ka)_{t1} - \log(\tau/Ka)_{t2}$$

To obtain Bias Factor comparison for two different responses, rep1 and rep2, treatment biases is then given by

$$\Delta\Delta\log(\tau/Ka) = \Delta\log(\tau/Ka)_{rep1} - \Delta\log(\tau/Ka)_{rep2}$$

and the Bias Factor is the exponential of the latter,

$$BF = 10^{\Delta\Delta\log(\tau/Ka)}$$

Finally, standard deviation on Ligand Biases are determined by the standard deviation of the relative effectiveness, the latter being determined by the data-fitting procedure. After standard calculus, mean bias factor together with their standard error were evaluated from the data. Finally, two-way unpaired t-test was performed to obtain the significance of the Bias Factors.

### 3. Results

#### 3.1. Effects of ADX compounds on LH/CGR-mediated cAMP production

First, we confirmed the antagonistic effect of ADX68692 and ADX68693 on FSHR-promoted cAMP production in transfected HEK293 cells {Dias, 2014 #5026}. Indeed, using the Glosensor™ cAMP assay, we clearly demonstrated a dose-dependent inhibition of FSH-induced cAMP production in HEK293 cells stably expressing FSHR, with an IC<sub>50</sub> values around μM (**Fig. 1A**). Next, we examined the effect of the two compounds on LH/CGR-mediated cAMP production. Accordingly, bioluminescence resonance energy transfer (BRET)-based sensor assay previously reported {Ayoub, 2015 #4823} was conducted in which different doses of NAMs were combined with increasing doses of hCG as indicated. As shown in **Fig. 1B** and **C**, the dose-dependent response of hCG on its receptor is consistent with the previous study using similar assay {Ayoub, 2015 #4823}. Similarly to FSHR, both ADX68692 (**Fig. 1B**) and ADX68693 (**Fig. 1C**) inhibited LH/CGR-mediated cAMP production in dose-dependent manner and with a significant shift in hCG potency (EC<sub>50</sub>) without affecting its maximal response (E<sub>max</sub>). When both compounds were compared at sub-saturating concentration of the hormone (0.1 nM), ADX68693 appeared significantly more potent than ADX68692 at 1 μM and 10 μM (~1 log, *P* < 0.01) on LH/CGR (**Fig. 1D**). Finally, in order to demonstrate the specificity of both compounds on gonadotropin receptors, we tested another Gs-coupled receptor, the vasopressin 2 receptor (V2R). As shown in **Fig. 1E**, neither ADX68692 nor ADX68693 (10 μM) affected V2R-mediated cAMP production

assessed with the same BRET-based sensor assay. Together, our results confirm the previous data showing ADX68692 and ADX68693 as FSHR NAMs in primary granulosa cells {Dias, 2014 #5026} and clearly demonstrate that these compounds also inhibit Gs/cAMP pathway mediated by LH/CGR in HEK293 cells.

Next, real-time kinetics of cAMP production were performed using 20 minutes pretreatment with 10  $\mu$ M of NAMs followed by rapid activation with 1 nM of hCG. As shown in **Fig. 2A**, hCG nicely induced cAMP production in time-dependent manner and both NAMs blocking such responses to different extent. Interestingly, when comparing both NAMs, ADX68693 appeared significantly stronger than ADX68692 on LH/CGR-mediated response, which is consistent with the difference in the inhibitory effect at 1 nM of hCG shown in **Fig. 1B** (for ADX68692) and **C** (for ADX68693). In order to examine whether the NAMs could reverse the gonadotropin-mediated response, we performed real-time kinetics where cells were first stimulated with hCG and either NAM (10  $\mu$ M) being applied 5 minutes later. This resulted in rapid time-dependent decrease in hCG-promoted cAMP production (**Fig. 2B**), demonstrating the antagonistic action of the two NAMs even when the receptor is fully activated by hCG.

To link our data on Gs/cAMP pathway with a more integrated cellular response, a cAMP-responsive element (CRE)-driven luciferase reporter assay was implemented. This assay uses a pSOM-Luc plasmid coding for the firefly luciferase under the control of the CRE of the somatostatin 5' regulatory region, as previously reported {Troispoux, 1999 #5079}. The gonadotropin-promoted luciferase expression was assessed in HEK293 cells transiently co-expressing either FSHR used here as a positive control (**Fig. 3A**) or LH/CGR (**Fig. 3B**) stimulated with increasing concentrations of FSH or hCG, respectively. The treatment of cells with 10  $\mu$ M of ADX68692 or ADX68693 significantly diminished the maximal responses ( $E_{max}$ ) without affecting the potency ( $EC_{50}$ ) of FSH (**Fig. 3A**) and hCG (**Fig. 3B**) on their respective receptors. These data indicated a negative allosteric effect of the compounds on FSHR as well as LH/CGR. Together with the cAMP data, these data demonstrate the antagonism of both NAMs on the cAMP/PKA/CREB signaling pathways of LH/CGR. Moreover, the comparison between the two NAMs on LH/CGR showed ADX68693 stronger than ADX68692 ( $P < 0.01$  and  $0.001$  at 10 nM and 100 nM of hCG, respectively), which is consistent with the kinetic data shown in **Fig. 2**.

### 3.2. Effects of ADX compounds on $\beta$ -arrestin 2 recruitment to LH/CGR

Next, the effect of ADX68692 and ADX68693 on the recruitment of  $\beta$ -arrestin to the activated LH/CGR was investigated using BRET technology allowing the assessment of  $\beta$ -arrestin 2 recruitment, in real-time and in live cells. For this, cells co-expressing LH/CGR-Rluc8 (BRET donors) and yPET- $\beta$ -arrestin 2 (BRET acceptor) were used as previously reported {Ayoub, 2015 #4823}. As shown in **Fig. 4**, the dose-dependent response of hCG is consistent with the previous study using similar assay {Ayoub, 2015 #4823}. Consistent with gene reporter data shown in **Fig. 3**, increasing doses of both ADX68692 (**Fig. 4A**) and ADX68693 (**Fig. 4B**) strongly reduced hCG-promoted  $\beta$ -arrestin 2 recruitment, with maximal effect observed at 10  $\mu$ M of NAMs indicating a negative allosteric effect. The comparison between the two NAMs at the maximal response of the hormone (100 nM) showed that ADX68693 was more potent than ADX68692 ( $\sim 1$  log,  $P < 0.005$  at 0.5  $\mu$ M and 1  $\mu$ M of NAMs,) on LH/CGR even if no difference in their maximal efficacy to inhibit hCG-promoted  $\beta$ -arrestin 2 recruitment was observed (**Fig. 4C**). Again, we used the recruitment of  $\beta$ -arrestin 2 to V2R as a negative control, showing that neither ADX68692 nor ADX68693 affected agonist-promoted V2R- $\beta$ -arrestin 2 association (**Fig. 4D**) and further demonstrating the specificity of these compounds on gonadotropin receptors.

In addition, real-time kinetics was performed using 10  $\mu$ M of NAMs and 100 nM of hCG. After 20 minutes of pre-treatment with either ADX68692 or ADX68693, a total inhibition of hCG-promoted  $\beta$ -arrestin 2 recruitment was observed with both NAMs (**Fig. 4E**). Such an inhibition is consistent with that observed in dose-response analysis (**Fig. 4A** and **B**) In order to examine whether hCG-mediated  $\beta$ -arrestin 2 response could be reversed with the NAMs, we performed real-time kinetics where cells were first stimulated with hCG to promote  $\beta$ -arrestin 2 recruitment and 12 minutes later either NAM (10  $\mu$ M) was applied. Interestingly, the addition of NAMs very rapidly inhibited  $\beta$ -arrestin 2 recruitment, indicating that the action of the two compounds occurred even when the receptor is fully activated by hCG (**Fig. 4F**). Together these data demonstrate the profound inhibition of  $\beta$ -arrestin recruitment to LH/CGR by ADX68692 and ADX68693.

### 3.3. Effect of ADX compounds on LH/CGR-mediated steroidogenesis in mLTC-1 cells

In order to link the foregoing data on LH/CGR in transfected HEK293 cells to

a more integrated physiological response, a murine Leydig tumor cell line (mLTC-1), known to endogenously express LHR and to trigger hCG responses {Legardinier, 2005 #5009} was used. Antagonistic effects of ADX68692 (**Fig. 5A**) and ADX68693 (**Fig. 5B**) on hCG-promoted cAMP production in mLTC-1 cells was confirmed, with strong inhibition at 10  $\mu$ M of NAMs. This was observed even when high concentrations of hCG were used, consistent with the NAM action of the two compounds observed in the gene reporter assay in HEK293 cells (**Fig. 3**). Furthermore, the data in mLTC-1 cells are consistent with cAMP data obtained in HEK293 cells since ADX68693 led to significantly stronger inhibition (**Fig. 5B**) than ADX68692 (**Fig. 5A**) ( $P < 0.05$  for 1 and 10 nM of hCG or  $P < 0.01$  for 100 nM of hCG).

Next, we examined the effects of ADX68692 and ADX68693 (10  $\mu$ M) on progesterone and testosterone production induced by hCG stimulation of mLTC-1 cells using HTRF®-based assays. As shown in **Fig. 5C**, neither ADX68692 nor ADX68693 significantly reduced hCG-induced progesterone production ( $P > 0.05$  when ADX68692 and ADX68693 were compared to DMSO from 0.1 to 100 nM of hCG). Interestingly, in testosterone assay, while ADX68692 partially inhibited hCG-promoted response, ADX68693 had a full antagonistic effect (**Fig. 5D**) ( $P < 0.001$  when ADX68692 and ADX68693 were compared each other from 0.1 to 100 nM of hCG). Together, these observations of antagonistic effects of the two NAMs in mLTC-1 cells suggest that their activity at the LHR is biased.

Both ADX68692 and ADX68693 show significant bias toward progesterone production compared to cAMP response (Bias factor of 5,93 (p-value = 0.046) and 11,64 (p-value = 0,08, respectively for ADX68692 and ADX68693 compared to DMSO) and to a certain extent toward testosterone compared to cAMP response (Bias factor of 2,31 (p-value = 0.18) and 3,68 (p-value = 0,73, respectively for ADX68692 and ADX68693 compared to DMSO). Steroids production is also slightly biased towards progesterone compared to testosterone.

Finally, while comparing both compounds effects with each other, ADX68693 is moderately biased with respect to Progesterone production compared to cAMP and Testosterone (Bias factor of 1,96 and 4,82 respectively, although p-value are not significant).



#### 4. Discussion

Two compounds, ADX68692 and ADX68693, have been recently reported to act as NAMs at the FSHR, leading to the inhibition of FSH-promoted steroidogenesis in rat granulosa primary cells and follicle maturation *in vivo* {Dias, 2014 #5026}. Interestingly, despite their structural similarities, the two molecules presented different antagonistic profiles at the FSHR. Indeed, while ADX68692 blocked FSHR-promoted cAMP production and progesterone as well as estradiol production, ADX68693 inhibited cAMP and progesterone with the same efficacy as ADX68692 but did not block estradiol production {Dias, 2014 #5026}. Thus, because of structural and signaling similarities between FSHR and LH/CGR, as well as their implication in the physiology of reproduction, the effects of ADX68692 and ADX68693 were studied on LH/CGR. We investigated the effects on the two major transduction mechanisms known to operate at the LH/CGR: Gs/cAMP/PKA and  $\beta$ -arrestins. Those studies were extended to examine the compounds' effects on the control of steroidogenesis using mLTC-1 cells endogenously expressing LHR. Together, our data clearly demonstrated that both ADX68692 and ADX68693 inhibited LH/CGR activation by hCG in HEK293 and mLTC-1 cells. Indeed, both cAMP production and  $\beta$ -arrestin recruitment induced by hCG were inhibited in dose-dependent manner. Moreover, differential inhibition of hCG-promoted steroid production by ADX68692 and ADX68693 in mLTC-1 cells was observed. These constitute the first small molecules antagonizing LH/CGR since only agonist compounds were reported so far for this receptor {Jorand-Lebrun, 2007 #5033} {van de Lagemaat, 2009 #5062} {van Koppen, 2008 #5066} {Bonger, 2011 #5023}. This finding is of great importance regarding the potential application of ADX68692 and ADX68693 to control the reproductive activity, knowing the involvement of both FSHR and LH/CGR in this function and their co-expression within the same cells at specific stages of female reproductive cycle. In fact, the physiological effects of FSH and LH on the ovary are characterized by the stimulation of the production of estradiol and progesterone, which play key roles in ovarian function and control of the reproductive cycle {Amsterdam, 1997 #5220} {Ascoli, 2002 #3127} {Amsterdam, 1997 #5222}. The mechanisms involved in the regulation of progesterone production by ovarian granulosa cells imply the activation of Gs/cAMP/PKA pathway leading to the modulation of gene expression associated with steroidogenesis such as the steroidogenic acute regulatory protein

(StAR), 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ HSD), and the cytochrome P450 (P450<sub>scc</sub>) enzyme system {Omura, 1995 #5154}{Stocco, 2000 #5177}{Strauss, 1999 #5181}{Weisser, 2011 #5198}. Other studies also reported a crosstalk between ERK activation and progesterone production downstream of PKA, with ERK exerting a negative feedback on steroid production {Seeger, 2001 #5214}. For LH/CGR, other molecular mechanisms, including its transactivation with EGFR were proposed to play role in steroidogenesis and thereby oocyte maturation and in gonadotropin-stimulated follicles {Jamnongjit, 2005 #5130}. Taken together with the previous data on FSHR {Dias, 2014 #5026}, our study using ADX68692 and ADX68693 highlighted the complexity of the mechanisms involved in the control of steroidogenesis via FSHR and LH/CGR.

In cAMP assay, the allosteric antagonism of both NAMs was also shown to reverse gonadotropin-induced cAMP production in real-time kinetic assay (**Fig. 2**). The relatively slow kinetics of such inhibition is likely due to strong accumulation of cAMP before the addition of NAMs since the assay is based on intracellular cAMP using BRET sensor. Moreover, kinetic and dose-response analysis indicated that ADX68693 is more efficacious than ADX68692 to inhibit hCG-promoted cAMP production in HEK293 cells. The fact that there was no significant difference in NAMs' efficacies on LH/CGR-mediated cAMP response in HEK203 cells is likely due to the high level of receptor expression achieved in this system. Indeed, we recently reported that in a similar experimental setting, maximal cAMP response could be reached with less than 5% of receptor occupied {Ayoub, 2015 #4823}, meaning that a substantial amount of spare receptors are available thereby preventing the NAMs to reduce maximum efficacies and rather leading to shifts in EC<sub>50</sub> values of hCG {Lohse, 1991 #5266}{Lohse, 1986 #3463}. In mLTC-1 cells, ADX68693 inhibited hCG-induced cAMP production more strongly than ADX68692 with both compounds profoundly decreasing the maximal response. Again, this is likely a reflection of mLTC-1 cells expressing less receptors, hence less spare receptors, than transfected HEK293 cells. These data were also consistent with the reporter gene assay indicating downstream inhibition of cAMP/PKA/CREB-dependent pathway.

In addition to Gs/cAMP pathway,  $\beta$ -arrestins are known to play a major role not only in the desensitization of GPCRs but also in their ability to signal independently of G proteins {Reiter, 2012 #3046}{Luttrell, 2002 #76}. Indeed,

many studies demonstrated the interaction of  $\beta$ -arrestins with gonadotropin receptors and, in some cases, their involvement in receptor signaling {Bhaskaran, 2003 #4037}{Ayoub, 2015 #4823}{Galet, 2008 #3325}{Kara, 2006 #3166}{Wehbi, 2010 #3156}{Tranchant, 2011 #3581}. Moreover, the role of  $\beta$ -arrestins in steroidogenic pathways has been demonstrated for aldosterone production mediated by the angiotensin II receptor (AT1R) {Lymperopoulos, 2011 #5142}{Lymperopoulos, 2009 #5135}. In the present study, we report that, at maximal dose (10  $\mu$ M), the two NAMs completely abolished  $\beta$ -arrestin 2 recruitment to LH/CGR. Real-time kinetics showed that both NAMs very rapidly reversed hCG-promoted  $\beta$ -arrestin 2 recruitment in HEK293 cells. The fact that, in the same cellular system (i.e.: transfected HEK293 cells), the NAMs led to a shift in  $EC_{50}$  for cAMP response whereas they had profound effects on hCG maximal response when measuring  $\beta$ -arrestin 2 recruitment is consistent with our previous finding that 100% receptor occupancy needs to be reached in order to achieve maximal  $\beta$ -arrestin recruitment {Ayoub, 2015 #4823}. This is nicely illustrated by the shift (3 logs) in hCG dose-response when  $\beta$ -arrestin 2 response was compared to cAMP response.

Interestingly, when we attempted to link our data on cAMP and  $\beta$ -arrestins observed in HEK293 cells to hCG-promoted steroid production in mLTC-1 cells, we generated data that were reminiscent of the previous study on FSHR {Dias, 2014 #5026}. In fact, this study showed that ADX68692 blocked FSHR-promoted cAMP production and progesterone as well as estradiol production, while ADX68693 acted with the same efficacy as ADX68692 on cAMP and progesterone inhibition but interestingly did not block estradiol production {Dias, 2014 #5026}. Our data on LHR showed that neither ADX6892 nor ADX68693 (10  $\mu$ M) had significant effects on progesterone production. In contrast, ADX6892 led to partial inhibition whereas ADX68693 completely abolished testosterone production induced by hCG. These data confirm better efficacy of ADX68693 compared to ADX68692 on LH/CGR. Moreover, this reveals interesting biased effects of both NAMs on LH/CGR: both NAMs blocked the canonical Gs/cAMP pathway, ADX68692 only partially inhibited hCG-induced testosterone but ADX68693 completely inhibited hCG-induced testosterone production and neither compounds significantly affected progesterone response. The original work on FSHR in rat granulosa primary cells {Dias, 2014 #5026} clearly support the link between cAMP pathway and

progesterone production, indicating that alternative and/or additional pathways are involved in estradiol production. In line with this, our data suggest that progesterone and testosterone production induced by LHR in mLTC-1 cells may not entirely depend on the cAMP pathway. Thus, progesterone and testosterone production seems to be controlled by distinct signaling pathways yet to be identified.

The total inhibition by both NAMs of  $\beta$ -arrestin recruitment to LH/CGR in HEK293 cells suggests that this transduction mechanism may play an important role in testosterone production. Together, these observations further illustrate the complexity of the mechanisms involved in the control of steroidogenesis *via* FSHR and LH/CGR. Such a discrepancy between cAMP/ $\beta$ -arrestin inhibition and steroid production is in fact difficult to reconcile with the classical view postulating that progesterone production depends on the activation of Gs/PKA/cAMP pathway. One possibility is the engagement of Gs- and  $\beta$ -arrestin-independent transduction mechanisms. Candidates include other G proteins (Gq/Gi) known to couple to both FSHR and LH/CGR (for review {Landomiel, 2014 #3838}) and could be differentially inhibited by the NAMs. Alternatively, the absence of significant inhibition of progesterone may be due to the residual cAMP response even upon treatment of mLTC-1 cells with NAMs. Moreover, our data cannot rule out the possibility of differential inhibition of intermediate pathways downstream cAMP as well as  $\beta$ -arrestins controlling steroid production. This may be consistent with the scenario where the activation of both Gs/cAMP and  $\beta$ -arrestin pathways would be involved to different extent (e.g.: with different activation thresholds) in the production of both progesterone and testosterone production. Differences in the kinetics of progesterone and testosterone production may also account for the observed biased effects between the two NAMs {Klein Herenbrink, 2016 #5272}.

Finally, this study demonstrates that ADX68692 and ADX68693 antagonized LH/CGR with differential profiles regarding their canonical Gs/cAMP and  $\beta$ -arrestin pathways. Even though their cross-reactivity on LH/CGR has yet to be demonstrated *in vivo*, our findings suggest that these compounds may impact the steroidogenic pathways differently as a function of FSHR and LH/CGR relative expression levels. Exploring this possibility will require further investigations *in vitro* and *in vivo*. It will be important to take into account the fact that the two

receptors are co-expressed in the same follicle cells at specific stages of female reproductive cycle. Interestingly, recent studies in transfected cells reported heterodimerization between FSHR and LH/CGR with the physiological relevance still to be demonstrated {Bonger, 2009 #4060}{Mazurkiewicz, 2015 #5237}{Feng, 2013 #5242}. Nevertheless, the intriguing possibility exists that the pharmacological profiles of the two NAMs on FSHR-LH/CGR heterodimer could be different compared to the respective protomers or homodimers. Furthermore, the differences in the biased effects of ADX68692 and ADX68693 with respect to steroid production that was previously observed on FSHR {Dias, 2014 #5026} and that our study revealed on LH/CGR as well, suggest that the combination of both NAMs may be required for efficient contraceptive or therapeutic applications to achieve full inhibition of steroidogenesis.

## **Acknowledgments**

This work was funded by ARTE2, MODUPHAC, “ARD2020 Biomédicament” grants from La Région Centre. MAA is funded by LE STUDIUM® Loire Valley Institute for Advanced Studies and AgreeSkills Plus.

## References

## Figure Legends

**Fig. 1: Dose-response analysis of the effects of ADX compounds on cAMP production.** HEK293 cells stably expressing FSHR (**A**) or transiently co-expressing LH/CGR (**B**, **C**, and **D**) or V2R (**E**) with cAMP pGloSensor™-22F (**A**) or the cAMP-BRET sensor (**B**, **C**, **D**, and **E**), were used for dose-response analysis of hormone-promoted cAMP production. For this, cells were first pretreated or not 20 minutes with the different concentrations of ADX68692 or ADX68693 as indicated. Then, cells were stimulated or not 30 minutes with the increasing concentrations of FSH (**A**), hCG (**B** and **C**) or DDAVP (**E**) before luminescence and BRET measurements were performed. The curves in panel **D** were generated by pretreating cells with increasing concentrations of NAMs followed by stimulation with 0.1 nM of hCG. Data are means  $\pm$  SEM of three experiments performed in duplicate.

**Fig. 2: Real-time kinetics of the effects of ADX compounds on cAMP production.** HEK293 cells transiently co-expressing LH/CGR and the cAMP-BRET sensor were used for kinetic analysis of hCG-promoted cAMP production. For this, cells were first pretreated (**A**) or not (**B**) 20 minutes with either DMSO or 10  $\mu$ M of ADX68692 or ADX68693 as indicated. Then, BRET measurements were rapidly performed upon addition of 1 nM of hCG followed (**B**) or not (**A**) by NAMs addition as indicated. Data are representative of three experiments performed in triplicate.

**Fig. 3: Effects of ADX compounds on cAMP sensitive reporter gene expression.** HEK293 cells transiently co-expressing the cAMP sensitive reporter gene (pSOM-Luc) and either FSHR (**A**) or LH/CGR (**B**) were first starved overnight and pretreated or not 1 hour with ADX68692 or ADX68693 (10  $\mu$ M). Then cells were stimulated or not 6 hours with increasing concentrations of FSH (**A**) or hCG (**B**) before luciferase luminescence was measured using Bright-Glo™ luciferase assay. Data are means  $\pm$  SEM of four independent experiments performed in single point.

**Fig. 4: Effects of ADX compounds on  $\beta$ -arrestin 2 recruitment.** HEK293 cells transiently co-expressing yPET- $\beta$ -arrestin 2 and either LH/CGR-Rluc8 (**A**, **B**, **C**, **E** and **F**) or V2R-Rluc8 (**D**), were used for dose-response and real-time kinetic analysis of hormone-promoted BRET increases. For dose-responses, cells were first pretreated or not 20 minutes with the different concentrations of ADX68692 or ADX68693 as indicated. Then, cells were stimulated or not 30 minutes with the

increasing concentrations hCG or DDAVP before BRET measurements were performed. The curves in panel **C** were generated by pretreating cells with increasing concentrations of NAMs followed by stimulation with 100 nM of hCG. For the kinetics, cells were first pretreated (**A**) or not (**B**) 20 minutes with either DMSO or 10  $\mu$ M of ADX68692 or ADX68693 as indicated. Then, BRET measurements were rapidly performed upon addition of 100 nM of hCG followed (**B**) or not (**A**) by NAMs addition as indicated. Data are means  $\pm$  SEM of three experiments performed in duplicate.

**Fig. 5: Effects of ADX compounds on LHR activation in mLTC-1 cells.** mLTC-1 cells endogenously expressing LHR were used for cAMP, progesterone and testosterone production. For cAMP, cells were first pretreated or not 20 minutes with different concentrations of ADX68692 (**A**) or ADX68693 (**B**). Then, cells were stimulated or not 30 minutes with the increasing concentrations of hCG before cAMP production was assessed by HTRF<sup>®</sup>-based assay as described in Material and Methods. For steroid production, cells were first starved overnight and pretreated or not 1 hour with ADX68692 or ADX68693 (10  $\mu$ M). Then, cells were stimulated or not 24 hours with increasing concentrations of hCG before progesterone (**C**) and testosterone (**D**) production was quantified using HTRF<sup>®</sup>-based assay. Data are means  $\pm$  SEM of three independent experiments performed in duplicate.